@article{Sun2022315,

title = {Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)},

author = {Juxian Sun and Rongping Guo and Xinyu Bi and Mengchao Wu and Zhaoyou Tang and Wan Yee Lau and Shusen Zheng and Xuehao Wang and Jinming Yu and Xiaoping Chen and Jia Fan and Jiahong Dong and Yongjun Chen and Yunfu Cui and Chaoliu Dai and Chihua Fang and Shuang Feng and Zhili Ji and Weidong Jia and Ningyang Jia and Gong Li and Jing Li and Qiu Li and Jiangtao Li and Tingbo Liang and Lianxin Liu and Shichun Lu and Yi Lv and Yilei Mao and Yan Meng and Zhiqiang Meng and Feng Shen and Jie Shi and Huichuan Sun and Kaishan Tao and Gaojun Teng and Xuying Wan and Tianfu Wen and Liqun Wu and Jinglin Xia and Mingang Ying and Jian Zhai and Leida Zhang and Xuewen Zhang and Zhiwei Zhang and Haiping Zhao and Donghai Zheng and Xuting Zhi and Jie Zhou and Cuncai Zhou and Jian Zhou and Zhaochong Zeng and Kangshun Zhu and Minshan Chen and Jianqiang Cai and Shuqun Cheng},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134527843&doi=10.1159%2f000523997&partnerID=40&md5=357f3f94ca73ee3dda1e4f3b0fbfb828},

doi = {10.1159/000523997},

issn = {22351795},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Liver Cancer},

volume = {11},

number = {4},

pages = {315 – 328},

publisher = {S. Karger AG},

abstract = {Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials. © 2022 The Author(s).},

note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Park2022583,

title = {2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma},

author = {Joong-Won Park},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142044076&doi=10.3350%2fcmh.2022.0294&partnerID=40&md5=b5838b9c54cd59840bce79bac3c51b7c},

doi = {10.3350/cmh.2022.0294},

issn = {22872728},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Clinical and Molecular Hepatology},

volume = {28},

number = {4},

pages = {583 – 705},

publisher = {Korean Association for the Study of the Liver},

abstract = {Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC. © 2022 by Korean Association for the Study of the Liver.},

note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Kubo2022290,

title = {Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma},

author = {Shoji Kubo and Hiroji Shinkawa and Yoshinari Asaoka and Tatsuya Ioka and Hiroshi Igaki and Namiki Izumi and Takao Itoi and Michiaki Unno and Masayuki Ohtsuka and Takuji Okusaka and Masumi Kadoya and Masatoshi Kudo and Takashi Kumada and Norihiro Kokudo and Michiie Sakamoto and Yoshihiro Sakamoto and Hideyuki Sakurai and Tadatoshi Takayama and Osamu Nakashima and Yasushi Nagata and Etsuro Hatano and Kenichi Harada and Takamichi Murakami and Masakazu Yamamoto},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134222582&doi=10.1159%2f000522403&partnerID=40&md5=85a60f3437ed401dcf4b7154c820b351},

doi = {10.1159/000522403},

issn = {22351795},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Liver Cancer},

volume = {11},

number = {4},

pages = {290 – 314},

publisher = {S. Karger AG},

abstract = {This paper presents the first version of clinical practice guidelines for intrahepatic cholangiocarcinoma (ICC) established by the Liver Cancer Study Group of Japan. These guidelines consist of 1 treatment algorithm, 5 background statements, 16 clinical questions, and 1 clinical topic, including etiology, staging, pathology, diagnosis, and treatments. Globally, a high incidence of ICC has been reported in East and Southeast Asian countries, and the incidence has been gradually increasing in Japan and also in Western countries. Reported risk factors for ICC include cirrhosis, hepatitis B/C, alcohol consumption, diabetes, obesity, smoking, nonalcoholic steatohepatitis, and liver fluke infestation, as well as biliary diseases, such as primary sclerosing cholangitis, hepatolithiasis, congenital cholangiectasis, and Caroli disease. Chemical risk factors include thorium-232, 1,2-dichloropropane, and dichloromethane. CA19-9 and CEA are recommended as tumor markers for early detection and diagnostic of ICC. Abdominal ultrasonography, CT, and MRI are effective imaging modalities for diagnosing ICC. If bile duct invasion is suspected, imaging modalities for examining the bile ducts may be useful. In unresectable cases, tumor biopsy should be considered when deemed necessary for the differential diagnosis and drug therapy selection. The mainstay of treatment for patients with Child-Pugh class A or B liver function is surgical resection and drug therapy. If the patient has no regional lymph node metastasis (LNM) and has a single tumor, resection is the treatment of choice. If both regional LNM and multiple tumors are present, drug therapy is the first treatment of choice. If the patient has either regional LNM or multiple tumors, resection or drug therapy is selected, depending on the extent of metastasis or the number of tumors. If distant metastasis is present, drug therapy is the treatment of choice. Percutaneous ablation therapy may be considered for patients who are ineligible for surgical resection or drug therapy due to decreased hepatic functional reserve or comorbidities. For unresectable ICC without extrahepatic metastasis, stereotactic radiotherapy (tumor size ≤5 cm) or particle radiotherapy (no size restriction) may be considered. ICC is generally not indicated for liver transplantation, and palliative care is recommended for patients with Child-Pugh class C liver function. © 2022 The Author(s).},

note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Drenth2022,

title = {EASL Clinical Practice Guidelines on the management of cystic liver diseases},

author = {Joost Drenth and Thijs Barten and Hermien Hartog and Frederik Nevens and Richard Taubert and Roser Torra Balcells and Valerie Vilgrain and Tobias Böttler},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136308707&doi=10.1016%2fj.jhep.2022.06.002&partnerID=40&md5=6512ea0a342bbc506bce2aae3db9d063},

doi = {10.1016/j.jhep.2022.06.002},

issn = {01688278},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Hepatology},

publisher = {Elsevier B.V.},

abstract = {The advent of enhanced radiological imaging techniques has facilitated the diagnosis of cystic liver lesions. Concomitantly, the evidence base supporting the management of these diseases has matured over the last decades. As a result, comprehensive clinical guidance on the subject matter is warranted. These Clinical Practice Guidelines cover the diagnosis and management of hepatic cysts, mucinous cystic neoplasms of the liver, biliary hamartomas, polycystic liver disease, Caroli disease, Caroli syndrome, biliary hamartomas and peribiliary cysts. On the basis of in-depth review of the relevant literature we provide recommendations to navigate clinical dilemmas followed by supporting text. The recommendations are graded according to the Oxford Centre for Evidence-Based Medicine system and categorised as ‘weak’ or ‘strong’. We aim to provide the best available evidence to aid the clinical decision-making process in the management of patients with cystic liver disease. © 2022 European Association for the Study of the Liver},

note = {Cited by: 0; All Open Access, Bronze Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Nault2022,

title = {Benign liver tumours: understanding molecular physiology to adapt clinical management},

author = {Jean-Charles Nault and Valérie Paradis and Maxime Ronot and Jessica Zucman-Rossi},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134344871&doi=10.1038%2fs41575-022-00643-5&partnerID=40&md5=78deb8b9fa10ec5964c11e36e77eedb5},

doi = {10.1038/s41575-022-00643-5},

issn = {17595045},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Nature Reviews Gastroenterology and Hepatology},

publisher = {Nature Research},

abstract = {Improvements in understanding the pathophysiology of the different benign liver nodules have refined their nosological classification. New criteria have been identified using imaging, histology and molecular analyses for a precise diagnosis of these tumours. Improvement in the classification of liver tumours provides a more accurate prediction of disease progression and has modified patient management. Haemangioma and focal nodular hyperplasia, the most common benign liver tumours that develop in the absence of chronic liver disease, are usually easy to diagnose on imaging and do not require specific treatment. However, hepatocellular adenomas and cirrhotic macronodules can be difficult to discriminate from hepatocellular carcinoma. The molecular subtyping of hepatocellular adenomas in five major subgroups defined by HNF1A inactivation, β-catenin mutation in exon 3 or exon 7/8, and activation of inflammatory or Hedgehog pathways helps to identify the tumours at risk of malignant transformation or bleeding. New clinical, biological and molecular tools have gradually been included in diagnostic and treatment algorithms to classify benign liver tumours and improve patient management. This Review aims to explain the main pathogenic mechanisms of benign liver tumours and how this knowledge could influence clinical practice. © 2022, Springer Nature Limited.},

note = {Cited by: 0},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Gotohda202216,

title = {Expert Consensus Guidelines: How to safely perform minimally invasive anatomic liver resection},

author = {Naoto Gotohda and Daniel Cherqui and David A. Geller and Mohammed Abu Hilal and Giammauro Berardi and Ruben Ciria and Yuta Abe and Takeshi Aoki and Horacio J. Asbun and Albert C. Y. Chan and Rawisak Chanwat and Kuo-Hsin Chen and Yajin Chen and Tan To Cheung and David Fuks and Ho-Seong Han and Kiyoshi Hasegawa and Etsuro Hatano and Goro Honda and Osamu Itano and Yukio Iwashita and Hironori Kaneko and Yutaro Kato and Ji Hoon Kim and Rong Liu and Santiago López-Ben and Mamoru Morimoto and Kazuteru Monden and Fernando Rotellar and Yoshihiro Sakamoto and Atsushi Sugioka and Tomoharu Yoshiizumi and Keiichi Akahoshi and Felipe Alconchel and Shunichi Ariizumi and Andrea Benedetti Cacciaguerra and Manuel Durán and Alain Garcia Vazquez and Nicolas Golse and Yoshihiro Miyasaka and Yasuhisa Mori and Satoshi Ogiso and Chikara Shirata and Federico Tomassini and Takeshi Urade and Taiga Wakabayashi and Hitoe Nishino and Taizo Hibi and Norihiro Kokudo and Masayuki Ohtsuka and Daisuke Ban and Yuichi Nagakawa and Takao Ohtsuka and Minoru Tanabe and Masafumi Nakamura and Masakazu Yamamoto and Akihiko Tsuchida and Go Wakabayashi},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120333965&doi=10.1002%2fjhbp.1079&partnerID=40&md5=0d8416f2da4ced3e0e385cddfa049f97},

doi = {10.1002/jhbp.1079},

issn = {18686974},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Hepato-Biliary-Pancreatic Sciences},

volume = {29},

number = {1},

pages = {16 – 32},

publisher = {John Wiley and Sons Inc},

abstract = {Background: The concept of minimally invasive anatomic liver resection (MIALR) is gaining popularity. However, specific technical skills need to be acquired to safely perform MIALR. The “Expert Consensus Meeting: Precision Anatomy for Minimally Invasive HBP Surgery (PAM-HBP Surgery Consensus)” was developed as a special program during the 32nd meeting of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Methods: Thirty-four international experts gathered online for the consensus. A Research Committee performed a comprehensive literature review, classifying studies according to the Scottish Intercollegiate Guidelines Network method. Based on the literature review and experts’ opinions, tentative recommendations were drafted and circulated among experts using online Delphi Rounds. Finally, formulated recommendations were presented online in the Expert Consensus Meeting of the JSHBPS on February 23rd, 2021. The final recommendations were validated and finalized by the 2nd Delphi Round in May 2021. Results: Seven clinical questions were selected, and 22 recommendations were formulated. All recommendations reached more than 85% consensus among experts at the final Delphi Round. Conclusions: The Expert Consensus Meeting for safely performing MIALR has presented a set of clinical guidelines based on available literature and experts’ opinions. We expect these guidelines to have a favorable effect on the safe implementation and development of MIALR. © 2021 Japanese Society of Hepato-Biliary-Pancreatic Surgery},

note = {Cited by: 6},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Shimizu2022709,

title = {Evidence-based clinical practice guidelines for chronic pancreatitis 2021},

author = {Kyoko Shimizu and Tetsuhide Ito and Atsushi Irisawa and Takao Ohtsuka and Hirotaka Ohara and Atsushi Kanno and Mitsuhiro Kida and Junichi Sakagami and Naohiro Sata and Yoshifumi Takeyama and Junko Tahara and Morihisa Hirota and Nao Fujimori and Atsushi Masamune and Satoshi Mochida and Nobuyuki Enomoto and Tooru Shimosegawa and Kazuhiko Koike},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136547609&doi=10.1007%2fs00535-022-01911-6&partnerID=40&md5=3bd223fa4dad73fb295975764c146908},

doi = {10.1007/s00535-022-01911-6},

issn = {09441174},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Gastroenterology},

volume = {57},

number = {10},

pages = {709 – 724},

publisher = {Springer},

abstract = {Background: Chronic pancreatitis (CP) is defined according to the recently proposed mechanistic definition as a pathological fibro-inflammatory syndrome of the pancreas in individuals with genetic, environmental, and/or other risk factors who develop persistent pathological responses to parenchymal injury or stress. Methods: The clinical practice guidelines for CP in Japan were revised in 2021 based on the 2019 Japanese clinical diagnostic criteria for CP, which incorporate the concept of a pathogenic fibro-inflammatory syndrome in the pancreas. In this third edition, clinical questions are reclassified into clinical questions, background questions, and future research questions. Results: Based on analysis of newly accumulated evidence, the strength of evidence and recommendations for each clinical question is described in terms of treatment selection, lifestyle guidance, pain control, treatment of exocrine and endocrine insufficiency, and treatment of complications. A flowchart outlining indications, treatment selection, and policies for cases in which treatment is ineffective is provided. For pain control, pharmacological treatment and the indications and timing for endoscopic and surgical treatment have been updated in the revised edition. Conclusions: These updated guidelines provide clinicians with useful information to assist in the diagnosis and treatment of CP. © 2022, The Author(s).},

note = {Cited by: 0; All Open Access, Green Open Access, Hybrid Gold Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takada20221057,

title = {JPN clinical practice guidelines 2021 with easy-to-understand explanations for the management of acute pancreatitis},

author = {Tadahiro Takada and Shuji Isaji and Toshihiko Mayumi and Masahiro Yoshida and Yoshifumi Takeyama and Takao Itoi and Keiji Sano and Yusuke Iizawa and Atsushi Masamune and Morihisa Hirota and Kohji Okamoto and Dai Inoue and Nobuya Kitamura and Yasuhisa Mori and Shuntaro Mukai and Seiki Kiriyama and Kunihiro Shirai and Asuka Tsuchiya and Ryota Higuchi and Teijiro Hirashita},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129146187&doi=10.1002%2fjhbp.1146&partnerID=40&md5=3ef1620f91bab2c49ba4f7dfc1fa90e9},

doi = {10.1002/jhbp.1146},

issn = {18686974},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Hepato-Biliary-Pancreatic Sciences},

volume = {29},

number = {10},

pages = {1057 – 1083},

publisher = {John Wiley and Sons Inc},

abstract = {Background: In preparing the Japanese (JPN) guidelines for the management of acute pancreatitis 2021, the committee focused the issues raised by the results of nationwide epidemiological survey in 2016 in Japan. Method: In addition to a systematic search using the previous JPN guidelines, papers published from January 2014 to September 2019 were searched for the contents to be covered by the guidelines based on the concept of GRADE system. Results: Thirty-six clinical questions (CQ) were prepared in 15 subject areas. Based on the facts that patients diagnosed with severe disease by both Japanese prognostic factor score and contrast-enhanced computed tomography (CT) grade had a high fatality rate and that little prognosis improvement after 2 weeks of disease onset was not obtained, we emphasized the importance of Pancreatitis Bundles, which were shown to be effective in improving prognosis, and the CQ sections for local pancreatic complications had been expanded to ensure adoption of a step-up approach. Furthermore, on the facts that enteral nutrition for severe acute pancreatitis was not started early within 48 h of admission and that unnecessary prophylactic antibiotics was used in almost all cases, we emphasized early enteral nutrition in small amounts even if gastric feeding is used and no prophylactic antibiotics are administered in mild pancreatitis. Conclusion: All the members of the committee have put a lot of effort into preparing the extensively revised guidelines in the hope that more people will have a common understanding and that better medical care will be spread. © 2022 Japanese Society of Hepato-Biliary-Pancreatic Surgery.},

note = {Cited by: 5},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Jaber2022,

title = {Guidelines for the management of patients with severe acute pancreatitis, 2021},

author = {Samir Jaber and Marc Garnier and Karim Asehnoune and Fanny Bounes and Louis Buscail and Jean-Baptiste Chevaux and Claire Dahyot-Fizelier and Lucie Darrivere and Matthieu Jabaudon and Olivier Joannes-Boyau and Yoann Launey and Eric Levesque and Philippe Levy and Philippe Montravers and Laurent Muller and Thomas Rimmelé and Claire Roger and Céline Savoye-Collet and Philippe Seguin and Jean-Pierre Tasu and Ronan Thibault and Geoffroy Vanbiervliet and Emmanuel Weiss and Audrey De Jong},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130554795&doi=10.1016%2fj.accpm.2022.101060&partnerID=40&md5=1e705243013a8598f9f3f165688c3ea4},

doi = {10.1016/j.accpm.2022.101060},

issn = {23525568},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Anaesthesia Critical Care and Pain Medicine},

volume = {41},

number = {3},

publisher = {Elsevier Masson s.r.l.},

abstract = {Objective: To provide guidelines for the management of the intensive care patient with severe acute pancreatitis. Design: A consensus committee of 22 experts was convened. A formal conflict-of-interest (COI) policy was developed at the beginning of the process and enforced throughout. The entire guideline construction process was conducted independently of any industrial funding (i.e. pharmaceutical, medical devices). The authors were required to follow the rules of the Grading of Recommendations Assessment, Development and Evaluation (GRADE®) system to guide assessment of quality of evidence. The potential drawbacks of making strong recommendations in the presence of low-quality evidence were emphasised. Methods: The most recent SFAR and SNFGE guidelines on the management of the patient with severe pancreatitis were published in 2001. The literature now is sufficient for an update. The committee studied 14 questions within 3 fields. Each question was formulated in a PICO (Patients Intervention Comparison Outcome) format and the relevant evidence profiles were produced. The literature review and recommendations were made according to the GRADE® methodology. Results: The experts' synthesis work and their application of the GRADE® method resulted in 24 recommendations. Among the formalised recommendations, 8 have high levels of evidence (GRADE 1+/−) and 12 have moderate levels of evidence (GRADE 2+/−). For 4 recommendations, the GRADE method could not be applied, resulting in expert opinions. Four questions did not find any response in the literature. After one round of scoring, strong agreement was reached for all the recommendations. Conclusions: There was strong agreement among experts for 24 recommendations to improve practices for the management of intensive care patients with severe acute pancreatitis. © 2022},

note = {Cited by: 2; All Open Access, Bronze Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Strand2022,

title = {AGA Clinical Practice Update on the Endoscopic Approach to Recurrent Acute and Chronic Pancreatitis: Expert Review},

author = {Daniel S. Strand and Ryan J. Law and Dennis Yang and B. Joseph Elmunzer},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136313810&doi=10.1053%2fj.gastro.2022.07.079&partnerID=40&md5=c1c3ef7273b7cc0697726a4153ddd448},

doi = {10.1053/j.gastro.2022.07.079},

issn = {00165085},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Gastroenterology},

publisher = {W.B. Saunders},

abstract = {Description: The purpose of this American Gastroenterological Association (AGA) Clinical Practice Update Expert Review is to provide practical, evidence-based guidance to clinicians regarding the role of endoscopy for recurrent acute and chronic pancreatitis. Methods: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide guidance on a topic of clinical importance to the AGA membership, underwent internal peer review by the Clinical Practice Updates Committee (CPUC), and external peer review through standard procedures of Gastroenterology. This review is framed around the 8 best practice advice points agreed upon by the authors, based on the results of randomized controlled trials, observational studies, systematic reviews and meta-analyses, as well expert consensus in this field. Best Practice Advice Statements BEST PRACTICE ADVICE 1: After an unrevealing initial evaluation, endoscopic ultrasound is the preferred diagnostic test for unexplained acute and recurrent pancreatitis. Magnetic resonance imaging with contrast and cholangiopancreatography is a reasonable complementary or alternative test to endoscopic ultrasound, based on local expertise and availability. BEST PRACTICE ADVICE 2: The role of endoscopic retrograde cholangiopancreatography (ERCP) for reducing the frequency of acute pancreatitis episodes in patients with pancreas divisum is controversial, but minor papilla endotherapy may be considered, particularly for those with objective signs of outflow obstruction, such as a dilated dorsal pancreatic duct and/or santorinicele. There is no role for ERCP to treat pain alone in patients with pancreas divisum. BEST PRACTICE ADVICE 3: The role of ERCP for reducing the frequency of pancreatitis episodes in patients with unexplained recurrent acute pancreatitis and standard pancreatic ductal anatomy is controversial and should only be considered after a comprehensive discussion of the uncertain benefits and potentially severe procedure-related adverse events. When pursued, ERCP with biliary sphincterotomy alone may be preferable to dual sphincterotomy. BEST PRACTICE ADVICE 4: Surgical intervention should be considered over endoscopic therapy for long-term treatment of patients with painful obstructive chronic pancreatitis. Endoscopic intervention is a reasonable alternative to surgery for suboptimal operative candidates or those who favor a less invasive approach, assuming they are clearly informed that the best practice advice primarily favors surgery. BEST PRACTICE ADVICE 5: When ERCP is pursued, small (≤5mm) main pancreatic duct stones can be treated with pancreatography and conventional stone extraction maneuvers. For larger stones, extracorporeal shockwave lithotripsy and/or pancreatoscopy with intraductal lithotripsy may be required. BEST PRACTICE ADVICE 6: When ERCP is pursued, prolonged stent therapy (6–12 months) is effective for treating symptoms and remodeling main pancreatic duct strictures. The preferred approach is to place and sequentially add multiple plastic stents in parallel (upsizing); emerging evidence suggests that fully covered self-expanding metal stents may have a role for this indication, but additional research is necessary. BEST PRACTICE ADVICE 7: ERCP with stent insertion is the preferred treatment for benign biliary stricture due to chronic pancreatitis. FCSEMS placement is favored over multiple plastic stents whenever feasible, given similar efficacy but significantly reduced need for stent exchange procedures during the treatment course. BEST PRACTICE ADVICE 8: Celiac plexus block should not be routinely performed for the management of pain due to chronic pancreatitis. The decision to proceed with celiac plexus block in selected patients with debilitating pain in whom other therapeutic measures have failed can be considered on a case-by-case basis, but only after discussion of the unclear outcomes of this intervention and its procedural risks. © 2022 AGA Institute},

note = {Cited by: 0; All Open Access, Bronze Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Laterre2022,

title = {Improving the management of severe acute pancreatitis: The new guidelines from the French Society of Anaesthesia and Intensive Care Medicine},

author = {Pierre-François Laterre and Christine Collienne},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132330222&doi=10.1016%2fj.accpm.2022.101103&partnerID=40&md5=0aca8b84e86a40603ac72e75f87e9967},

doi = {10.1016/j.accpm.2022.101103},

issn = {23525568},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Anaesthesia Critical Care and Pain Medicine},

volume = {41},

number = {3},

publisher = {Elsevier Masson s.r.l.},

note = {Cited by: 0},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Marchegiani2022663,

title = {Postpancreatectomy Acute Pancreatitis (PPAP): Definition and Grading from the International Study Group for Pancreatic Surgery (ISGPS)},

author = {Giovanni Marchegiani and Savio George Barreto and Elisa Bannone and Michael Sarr and Charles M. Vollmer and Saxon Connor and Massimo Falconi and Marc G. Besselink and Roberto Salvia and Christopher L. Wolfgang and Nicholas J. Zyromski and Charles J. Yeo and Mustapha Adham and Ajith K. Siriwardena and Kyoichi Takaori and Mohammad Abu Hilal and Martin Loos and Pascal Probst and Thilo Hackert and Oliver Strobel and Olivier R. C. Busch and Keith D. Lillemoe and Yi Miao and Christopher M. Halloran and Jens Werner and Helmut Friess and Jakob R. Izbicki and Maximillian Bockhorn and Yogesh K. Vashist and Kevin Conlon and Ioannis Passas and Luca Gianotti and Marco Del Chiaro and Richard D. Schulick and Marco Montorsi and Attila Oláh and Giuseppe Kito Fusai and Alejandro Serrablo and Alessandro Zerbi and Abe Fingerhut and Roland Andersson and Robert Padbury and Christos Dervenis and John P. Neoptolemos and Claudio Bassi and Markus W. Büchler and Shailesh V. Shrikhande},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122945187&doi=10.1097%2fSLA.0000000000005226&partnerID=40&md5=adaa04de8a92f6dcf49d8dd2f6b185f6},

doi = {10.1097/SLA.0000000000005226},

issn = {00034932},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Annals of Surgery},

volume = {275},

number = {4},

pages = {663 – 672},

publisher = {Lippincott Williams and Wilkins},

abstract = {Objective:The ISGPS aimed to develop a universally accepted definition for PPAP for standardized reporting and outcome comparison.Background::PPAP is an increasingly recognized complication after partial pancreatic resections, but its incidence and clinical impact, and even its existence are variable because an internationally accepted consensus definition and grading system are lacking.Methods:The ISGPS developed a consensus definition and grading of PPAP with its members after an evidence review and after a series of discussions and multiple revisions from April 2020 to May 2021.Results:We defined PPAP as an acute inflammatory condition of the pancreatic remnant beginning within the first 3 postoperative days after a partial pancreatic resection. The diagnosis requires (1) a sustained postoperative serum hyperamylasemia (POH) greater than the institutional upper limit of normal for at least the first 48 hours postoperatively, (2) associated with clinically relevant features, and (3) radiologic alterations consistent with PPAP. Three different PPAP grades were defined based on the clinical impact: (1) grade postoperative hyperamylasemia, biochemical changes only; (2) grade B, mild or moderate complications; and (3) grade C, severe life-threatening complications.Discussions:The present definition and grading scale of PPAP, based on biochemical, radiologic, and clinical criteria, are instrumental for a better understanding of PPAP and the spectrum of postoperative complications related to this emerging entity. The current terminology will serve as a reference point for standard assessment and lend itself to developing specific treatments and prevention strategies. © 2022 Lippincott Williams and Wilkins. All rights reserved.},

note = {Cited by: 9},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ban2022161,

title = {International Expert Consensus on Precision Anatomy for minimally invasive distal pancreatectomy: PAM-HBP Surgery Project},

author = {Daisuke Ban and Hitoe Nishino and Takao Ohtsuka and Yuichi Nagakawa and Mohammed Abu Hilal and Horacio J. Asbun and Ugo Boggi and Brian K. P. Goh and Jin He and Goro Honda and Jin-Young Jang and Chang Moo Kang and Michael L. Kendrick and David A. Kooby and Rong Liu and Yoshiharu Nakamura and Kohei Nakata and Chinnusamy Palanivelu and Shailesh V. Shrikhande and Kyoichi Takaori and Chung-Ngai Tang and Shin-E Wang and Christopher L. Wolfgang and Anusak Yiengpruksawan and Yoo-Seok Yoon and Ruben Ciria and Giammauro Berardi and Giovanni Maria Garbarino and Ryota Higuchi and Naoki Ikenaga and Yoshiya Ishikawa and Shingo Kozono and Aya Maekawa and Yoshiki Murase and Yusuke Watanabe and Giuseppe Zimmitti and Filipe Kunzler and Zi-Zheng Wang and Leon Sakuma and Hiroaki Osakabe and Chie Takishita and Itaru Endo and Masao Tanaka and Hiroki Yamaue and Minoru Tanabe and Go Wakabayashi and Akihiko Tsuchida and Masafumi Nakamura},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120363013&doi=10.1002%2fjhbp.1071&partnerID=40&md5=8b0679e371c9ea9ea0ac2c31253e0768},

doi = {10.1002/jhbp.1071},

issn = {18686974},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Hepato-Biliary-Pancreatic Sciences},

volume = {29},

number = {1},

pages = {161 – 173},

publisher = {John Wiley and Sons Inc},

abstract = {Background: Surgical views with high resolution and magnification have enabled us to recognize the precise anatomical structures that can be used as landmarks during minimally invasive distal pancreatectomy (MIDP). This study aimed to validate the usefulness of anatomy-based approaches for MIDP before and during the Expert Consensus Meeting: Precision Anatomy for Minimally Invasive HBP Surgery (February 24, 2021). Methods: Twenty-five international MIDP experts developed clinical questions regarding surgical anatomy and approaches for MIDP. Studies identified via a comprehensive literature search were classified using Scottish Intercollegiate Guidelines Network methodology. Online Delphi voting was conducted after experts had drafted the recommendations, with the goal of obtaining >75% consensus. Experts discussed the revised recommendations in front of the validation committee and an international audience of 384 attendees. Finalized recommendations were made after a second round of online Delphi voting. Results: Four clinical questions were addressed, resulting in 10 recommendations. All recommendations reached at least a 75% consensus among experts. Conclusions: The expert consensus on precision anatomy for MIDP has been presented as a set of recommendations based on available evidence and expert opinions. These recommendations should guide experts and trainees in performing safe MIDP and foster its appropriate dissemination worldwide. © 2021 Japanese Society of Hepato-Biliary-Pancreatic Surgery},

note = {Cited by: 1},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Nagakawa2022124,

title = {International expert consensus on precision anatomy for minimally invasive pancreatoduodenectomy: PAM-HBP surgery project},

author = {Yuichi Nagakawa and Kohei Nakata and Hitoe Nishino and Takao Ohtsuka and Daisuke Ban and Horacio J. Asbun and Ugo Boggi and Jin He and Michael L. Kendrick and Chinnusamy Palanivelu and Rong Liu and Shin-E Wang and Chung-Ngai Tang and Kyoichi Takaori and Mohammed Abu Hilal and Brian K. P. Goh and Goro Honda and Jin-Young Jang and Chang Moo Kang and David A. Kooby and Yoshiharu Nakamura and Shailesh V. Shrikhande and Christopher L. Wolfgang and Anusak Yiengpruksawan and Yoo-Seok Yoon and Yusuke Watanabe and Shingo Kozono and Ruben Ciria and Giammauro Berardi and Giovanni Maria Garbarino and Ryota Higuchi and Naoki Ikenaga and Yoshiya Ishikawa and Aya Maekawa and Yoshiki Murase and Giuseppe Zimmitti and Filipe Kunzler and Zi-Zheng Wang and Leon Sakuma and Chie Takishita and Hiroaki Osakabe and Itaru Endo and Masao Tanaka and Hiroki Yamaue and Minoru Tanabe and Go Wakabayashi and Akihiko Tsuchida and Masafumi Nakamura},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120472637&doi=10.1002%2fjhbp.1081&partnerID=40&md5=18fa8cafdd195ef05ab903bfd3f73311},

doi = {10.1002/jhbp.1081},

issn = {18686974},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Hepato-Biliary-Pancreatic Sciences},

volume = {29},

number = {1},

pages = {124 – 135},

publisher = {John Wiley and Sons Inc},

abstract = {Background: The anatomical structure around the pancreatic head is very complex and it is important to understand its precise anatomy and corresponding anatomical approach to safely perform minimally invasive pancreatoduodenectomy (MIPD). This consensus statement aimed to develop recommendations for elucidating the anatomy and surgical approaches to MIPD. Methods: Studies identified via a comprehensive literature search were classified using the Scottish Intercollegiate Guidelines Network method. Delphi voting was conducted after experts had drafted recommendations, with a goal of obtaining >75% consensus. Experts discussed the revised recommendations with the validation committee and an international audience of 384 attendees. Finalized recommendations were made after a second round of online Delphi voting. Results: Three clinical questions were addressed, providing six recommendations. All recommendations reached at least a consensus of 75%. Preoperatively evaluating the presence of anatomical variations and superior mesenteric artery (SMA) and superior mesenteric vein (SMV) branching patterns was recommended. Moreover, it was recommended to fully understand the anatomical approach to SMA and intraoperatively confirm the SMA course based on each anatomical landmark before initiating dissection. Conclusions: MIPD experts suggest that surgical trainees perform resection based on precise anatomical landmarks for safe and reliable MIPD. © 2021 Japanese Society of Hepato-Biliary-Pancreatic Surgery},

note = {Cited by: 2},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Foley20223358,

title = {Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE},

author = {Kieran G. Foley and Max J. Lahaye and Ruedi F. Thoeni and Marek Soltes and Catherine Dewhurst and Sorin Traian Barbu and Yogesh K. Vashist and Søren Rafael Rafaelsen and Marianna Arvanitakis and Julie Perinel and Rebecca Wiles and Stuart Ashley Roberts},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121354313&doi=10.1007%2fs00330-021-08384-w&partnerID=40&md5=e244dfb80a773d07ec752c3661bc2cd6},

doi = {10.1007/s00330-021-08384-w},

issn = {09387994},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {European Radiology},

volume = {32},

number = {5},

pages = {3358 – 3368},

publisher = {Springer Science and Business Media Deutschland GmbH},

abstract = {Abstract: Main recommendations: 1.Primary investigation of polypoid lesions of the gallbladder should be with abdominal ultrasound. Routine use of other imaging modalities is not recommended presently, but further research is needed. In centres with appropriate expertise and resources, alternative imaging modalities (such as contrast-enhanced and endoscopic ultrasound) may be useful to aid decision-making in difficult cases. Strong recommendation, low–moderate quality evidence.2.Cholecystectomy is recommended in patients with polypoid lesions of the gallbladder measuring 10 mm or more, providing the patient is fit for, and accepts, surgery. Multidisciplinary discussion may be employed to assess perceived individual risk of malignancy. Strong recommendation, low-quality evidence.3.Cholecystectomy is suggested for patients with a polypoid lesion and symptoms potentially attributable to the gallbladder if no alternative cause for the patient’s symptoms is demonstrated and the patient is fit for, and accepts, surgery. The patient should be counselled regarding the benefit of cholecystectomy versus the risk of persistent symptoms. Strong recommendation, low-quality evidence.4.If the patient has a 6–9 mm polypoid lesion of the gallbladder and one or more risk factors for malignancy, cholecystectomy is recommended if the patient is fit for, and accepts, surgery. These risk factors are as follows: age more than 60 years, history of primary sclerosing cholangitis (PSC), Asian ethnicity, sessile polypoid lesion (including focal gallbladder wall thickening > 4 mm). Strong recommendation, low–moderate quality evidence.5.If the patient has either no risk factors for malignancy and a gallbladder polypoid lesion of 6–9 mm, or risk factors for malignancy and a gallbladder polypoid lesion 5 mm or less, follow-up ultrasound of the gallbladder is recommended at 6 months, 1 year and 2 years. Follow-up should be discontinued after 2 years in the absence of growth. Moderate strength recommendation, moderate-quality evidence.6.If the patient has no risk factors for malignancy, and a gallbladder polypoid lesion of 5 mm or less, follow-up is not required. Strong recommendation, moderate-quality evidence.7.If during follow-up the gallbladder polypoid lesion grows to 10 mm, then cholecystectomy is advised. If the polypoid lesion grows by 2 mm or more within the 2-year follow-up period, then the current size of the polypoid lesion should be considered along with patient risk factors. Multidisciplinary discussion may be employed to decide whether continuation of monitoring, or cholecystectomy, is necessary. Moderate strength recommendation, moderate-quality evidence.8.If during follow-up the gallbladder polypoid lesion disappears, then monitoring can be discontinued. Strong recommendation, moderate-quality evidence. Source and scope: These guidelines are an update of the 2017 recommendations developed between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery–European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE). A targeted literature search was performed to discover recent evidence concerning the management and follow-up of gallbladder polyps. The changes within these updated guidelines were formulated after consideration of the latest evidence by a group of international experts. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was adopted to define the strength of recommendations and the quality of evidence. Key Point: • These recommendations update the 2017 European guidelines regarding the management and follow-up of gallbladder polyps. © 2021, The Author(s).},

note = {Cited by: 7; All Open Access, Green Open Access, Hybrid Gold Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}